Covid-19 Vaccines, Therapies – 20 July 2020

BioRender Covid-19 vaccine and therapy tracker. (BioRender.com)

20 July 2020. A continuing feature on Science & Enterprise is a weekly statistical report of vaccines and therapies for Covid-19 offered by BioRender, a scientific illustration software company. BioRender, in Toronto, Ontario, develops graphics tools for life sciences, biotechnology, and other disciplines.

This week, the data show a sharp jump in new Covid-19 therapy projects, with 17 new treatments reported raising the total to 322. Two more of those therapies reached clinical trial stage last week, raising that number to 236. Likewise, two more Covid-19 vaccine initiatives are underway with now two more vaccines also in clinical trials, increasing those totals to 155 and 31 respectively.

In addition to the summary dashboard shown above, the BioRender Covid-19 vaccine and therapy page provides details of the vaccines and therapies, as well as an activity feed showing news updates on these drugs.

Last week, Science & Enterprise reported on some of those new vaccine and therapy developments. One story tells about preclinical tests of a new vaccine administered as a nasal spray, which according to its developer Altimmune Inc., invokes multiple immune responses. In another story last week, Adagio Therapeutics, a new company, is raising $50 million in venture capital for its engineered therapies to act against a range of coronaviruses, not just Covid-19.

More from Science & Enterprise:

• Covid-19 Vaccines, Therapies – 13 July 2020
• NIH Opens Covid-19 Clinical Trial Network
• EC, France Fund Universal Covid-19, Flu Vaccines
• BARDA to Buy $2B in Covid-19 Vaccines, Therapies
• Dual Antibodies in Trial to Prevent Covid-19 Infections

*     *     *